VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
HUM
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
HUMHumana Inc.
$461.12$55.4B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksHUMBalance Sheet

Humana Inc. (HUM) Balance Sheet

30Y historyFree accessUpdated daily

Total assets rose from $50.0B to $57.3B while equity moved only from $17.6B to $18.8B, with a debt-to-equity ratio of 0.73, suggesting moderate leverage but a balance sheet growing faster through liabilities than retained capital.

Income StatementBalance SheetCash FlowRatios

HUM Balance Sheet

Annual statement

HUM Balance Sheet

Humana Inc. (HUM) balance sheet — 30-year assets, liabilities & shareholders' equity history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Total Assets57.28B48.75B46.31B46.89B43.73B44.75B35.08B29.04B25.34B26.68B25.81B25.12B23.45B20.77B19.52B17.86B16.07B14.15B13.04B12.88B10.13B6.87B5.66B5.29B4.6B4.4B4.17B4.9B5.5B5.42B3.15B
Asset Growth %42.6%5.26%-1.24%7.24%-2.29%27.57%20.78%14.6%-5.02%3.38%2.74%7.13%12.9%6.42%9.29%11.12%13.55%8.52%1.26%27.17%47.42%21.42%6.88%15.07%4.46%5.68%-14.96%-10.84%1.44%71.84%9.56%
Total Investment Assets4M16.83B19.33B17.75B15.01B14.11B14.94B12.44B11.48B12.3B9.8B9.11B9.55B9.8B9.85B9.45B8.37B7.62B5.62B5.99B4.24B02.15B2B1.69B1.67B1.65B1.76B1.9B2.02B1.41B
Long-Term Investments19.97B16.83B19.33B17.75B15.01B14.11B14.94B12.44B11.48B12.3B9.8B9.11B9.55B9.8B9.85B9.45B8.37B7.62B5.62B5.99B4.24B00319.17M288.72M280.32M240M1.51B1.59B1.51B1.26B
Short-Term Investments18.17B0000000000000000000002.15B1.68B1.41B1.39B1.41B1.51B1.59B1.51B1.26B
Total Current Assets39.61B7.47B4.92B6.73B6.74B5.21B5.81B5.11B3.36B4.9B4.7B3.41B2.71B1.8B1.79B2.18B2.32B2.8B3.11B2.97B2.65B4.08B3.52B00000000
Cash & Equivalents6.93B4.2B2.22B4.69B5.06B3.39B4.67B4.05B2.34B4.04B3.88B2.57B1.94B1.14B1.31B1.38B1.67B1.61B1.97B2.04B1.74B732.02M580.08M931.4M721.36M651.42M658M978M913M627M322M
Receivables17.05B3.27B2.7B2.04B1.67B1.81B1.14B1.06B1.01B854M1.28B1.16B1.05B950M733M1.03B959M823.62M789.68M605.54M680.94M738.65M579.62M465.99M321.13M322.06M205.26M225M276M351M211M
Other Current Assets11.63B000000000-461M-319M-283M-287M-252M-230M-316.08M366.48M353.79M328.82M229.42M380.61M212.96M-3.07B-2.45B-2.36B-2.27B-2.71B-2.78B-2.48B-1.79B
Goodwill & Intangibles42.34B10.81B11.07B11.24B10.91B13.73B4.78B4.11B4.14B3.51B3.55B3.62B3.67B4.43B4.37B3.17B2.97B2.24B2.26B1.9B1.41B1.37B915.89M776.87M776.87M776.87M790M806M1.19B1.22B488M
Goodwill10.55B9.69B9.63B9.55B9.14B11.09B4.45B3.93B3.9B3.28B3.27B3.27B3.23B3.73B3.64B2.74B2.57B1.99B1.96B1.66B1.31B1.26B885.57M776.87M776.87M776.87M790M806M1.19B1.22B488M
Intangible Assets01.13B1.44B1.69B1.76B2.64B329M177M245M226M280M357M440M693M731M435M399.47M243.47M301.29M236.77M95.66M104.02M30.32M00000000
PP&E (Net)2.07B2.72B2.98B3.54B3.74B3.75B2.81B2.37B1.74B1.58B1.5B1.38B1.23B1.22B1.1B912M815.34M679.14M711.49M637.24M545M484.41M399.51M416.47M459.84M461.76M435M418M433M420M371M
Other Assets3.83B10.83B7.74B7.58B6.49B7.37B6.44B4.79B4.38B3.85B5.45B6.89B5.57B2.84B2.42B1.52B1.05B748.92M1.18B1.36B1.26B-1.92B823.92M00000000
Total Liabilities38.4B31.01B29.87B30.57B28.36B28.64B21.35B17.01B15.18B16.84B15.13B14.78B13.8B11.46B10.67B9.8B9.15B8.38B8.58B8.85B7.07B4.4B3.57B3.46B2.99B2.9B2.81B3.68B3.81B4.1B1.86B
Total Debt12.5B12.94B12.26B12.27B11.75B13.22B7.14B6.11B6.07B4.92B4.09B4.09B3.83B2.6B2.61B1.66B1.67B1.68B1.94B1.69B1.27B815.04M828.76M861.69M699.79M731.25M599.95M1.23B1.5B1.49B225M
Net Debt5.57B8.74B10.04B7.58B6.69B9.83B2.47B2.06B3.73B878M215M1.52B1.89B1.46B1.3B282M-4.29M64.58M-33.39M-352.63M-471.2M83.03M248.68M-69.71M-21.56M79.83M415M247M582M859M-97M
Long-Term Debt11.55B12.37B11.14B10.21B9.03B10.54B6.06B4.97B4.38B4.77B3.49B3.79B3.83B2.6B2.61B1.66B1.67B1.68B1.94B1.69B1.27B513.79M636.7M642.64M339.91M315.49M0324M1.01B1.49B225M
Short-Term Debt949M150M724M1.61B2.26B2.14B729M815M1.69B150M600M299M0000447K0000301.25M192.06M219.05M359.88M415.76M749M901M484M00
Total Current Liabilities24.05B10.31B11.26B11.95B11.63B10.49B9B6.8B6.53B4.37B5.44B5.64B4.84B4.1B4.01B3.97B3.66B3.45B3.44B2.92B2.64B3.05B2.1B2.26B2.39B2.31B2.67B0000
Accounts Payable9.39B9.81B10.27B10.07B9.08B8.1B7.95B5.74B4.55B3.84B4.56B4.98B4.47B3.89B3.78B3.75B3.47B3.22B3.21B2.7B2.49B01.91B000000471M1.47B
Deferred Revenue270M356M260M266M286M254M318M247M283M378M280M364M361M206M230M213M185.41M228.82M238.1M219.78M155.3M00333.07M335.76M325.04M333M0000
Other Current Liabilities13.44B0000000000027M-197M-94M-93M0-374.46M-224.54M-269.23M77.85M232.4M00552.69M00-2.66B-2.39B-633M-1.5B
Deferred Taxes00001000K1000K1000K1000K1000K1000K1000K1000K1000K1000K01000K1000K001000K1000K1000K000000000
Other Liabilities2.79B7.91B7.07B7.97B6.36B5.79B4.98B4.33B3.95B7.37B5.78B4.9B4.57B4.14B4.05B3.58B3.43B3.25B3.2B4.21B3.08B-624.81M828.39M-642.64M-245.03M-315.49M148.56M214.79M-573M-889M-225M
Total Equity18.89B17.74B16.45B16.32B15.37B16.1B13.73B12.04B10.16B9.84B10.69B10.35B9.65B9.32B8.85B8.06B6.92B5.78B4.46B4.03B3.05B2.47B2.09B1.84B1.61B1.51B1.36B1.27B1.69B1.5B1.29B
Equity Growth %19.51%7.86%0.78%6.17%-4.55%17.3%14.05%18.46%3.24%-7.89%3.28%7.26%3.54%5.3%9.72%16.45%19.88%29.59%10.63%31.93%23.43%18.37%13.84%14.28%6.53%10.88%7.26%-24.88%12.46%16.18%0.39%
Shareholders Equity18.82B17.66B16.38B16.26B15.31B16.08B13.73B12.04B10.16B9.84B10.69B10.35B9.65B9.32B8.85B8.06B6.92B5.78B4.46B4.03B3.05B2.47B2.09B1.84B1.61B1.51B1.36B1.27B1.69B1.5B1.29B
Minority Interest63M80M70M56M59M23M0000000000000000000000000
Retained Earnings30.8B29.07B28.32B27.54B25.49B23.09B20.52B17.48B15.07B13.67B11.45B11.02B9.92B8.94B7.88B6.83B5.53B4.43B3.39B2.74B1.91B1.54B1.23B949.81M720.88M578.12M461M371M753M624M451M
Common Stock33M33M33M33M33M33M33M33M33M33M33M33M33M33M32M32M31.71M31.63M31.31M31.12M30.49M29.84M29.34M28.98M28.56M28.45M28M28M28M27M27M
Accumulated OCI-1.27B-633M-1.07B-999M-1.3B42M391M156M-159M19M-66M58M223M158M386M303M120.58M42.13M-175.24M14.02M-13.21M24.83M16.53M16.91M22.45M11.67M-8M-28M13M9M-8M
Return on Equity (ROE)6.68%6.95%7.37%15.71%17.83%19.66%26.14%24.39%16.83%23.85%5.84%12.77%12.1%13.55%14.45%18.94%17.31%20.32%15.25%23.54%17.63%13.52%14.26%13%9.17%8.17%6.85%-25.87%8.09%12.39%0.93%
Return on Assets (ROA)2.28%2.5%2.59%5.49%6.34%7.35%10.5%9.95%6.47%9.33%2.41%5.25%5.19%6.11%6.54%8.36%7.27%7.65%4.99%7.25%5.74%4.92%5.11%4.52%3.17%2.73%1.99%-7.36%2.36%4.04%0.4%
Equity / Assets32.97%36.38%35.51%34.8%35.15%35.99%39.14%41.45%40.09%36.88%41.4%41.18%41.13%44.85%45.33%45.15%43.08%40.81%34.18%31.28%30.15%36.02%36.94%34.68%34.92%34.24%32.64%25.88%30.71%27.7%40.98%
Debt / Equity0.66x0.73x0.75x0.75x0.76x0.82x0.52x0.51x0.60x0.50x0.38x0.40x0.40x0.28x0.30x0.21x0.24x0.29x0.43x0.42x0.42x0.33x0.40x0.47x0.44x0.48x0.44x0.97x0.89x0.99x0.17x
Book Value per Share155.04146.80136.06131.13120.93124.45103.2189.3473.4267.6070.8068.4561.8858.5454.1248.0440.7834.1626.3823.7218.1715.0012.8411.329.349.018.167.5610.089.057.82
Tangible BV per Share68.4757.3044.4440.7835.1218.3367.3058.8743.4943.5147.2644.4938.3330.7327.3829.1323.3020.9412.9812.539.806.707.216.534.824.373.422.752.991.674.86

Key Metrics

Growth RegimeMixed
ProfitabilityWeak
Balance SheetAdequate
Cash FlowMixed
Top Statement Risk

Thin margins amid reserve volatility

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Asset Base Growing Faster Than Equity

Based on Humana's reported figures, total assets rose from $50.0B in 2024Q3 to $57.3B in 2026Q3, while equity grew more modestly from $17.6B to $18.8B, suggesting the balance sheet is expanding through liabilities rather than retained capital generation.

The gap between asset growth and equity growth implies that much of the expansion reflects higher policyholder obligations and float rather than internally generated capital. Equity returns have been uneven, with ROE swinging from 7.3% in 2025Q1 to negative 4.4% in 2025Q4, which limits the capacity of earnings to reinforce the capital base. Investors should monitor whether the asset expansion continues to outpace equity, as that would tighten the cushion available against adverse claims development.

Loss Ratio Swings Test Reserve Adequacy

According to reported quarterly data, Humana's loss ratio moved between 82.6% in 2025Q1 and 88.3% in both 2025Q4 and 2026Q3, indicating that claims cost relative to premiums has been volatile across the period.

A loss ratio that repeatedly climbs toward 88% leaves a narrow margin for reserve estimation error, and the quarterly pattern is consistent with year-end cost pressure. Without isolated prior-period development data in the supplied figures, it is not possible to determine whether these swings reflect true utilization trends or reserve true-ups. Investors should monitor reserve development disclosures closely, as persistent upward loss ratio drift would warrant further investigation into IBNR adequacy.

Low Leverage Offset by Modest Returns

Based on Humana's reported figures, the debt-to-equity ratio of 0.73 and ROE of 7.0% indicate moderate leverage paired with returns that appear thin relative to the capital base held.

Leverage at this level suggests the balance sheet retains some capacity for absorbing shocks, but the sub-8% ROE indicates that the equity base is not generating strong returns in the current cycle. Statutory capital adequacy metrics such as RBC ratios are not included in the supplied data, so capacity for buybacks or acquisitions cannot be assessed with confidence. The conservative leverage profile may provide flexibility, though its benefit depends on earnings stabilizing.

Cash Position Undisclosed Against Claims Outflows

As reported in financial statements, claims and loss outflows reached $36.3B in 2026Q3, yet the supplied cash line shows no reported balance, leaving the liquid asset coverage of expected payouts data unavailable.

Because cash and reinsurance recoverable figures are not provided, the ratio of liquid assets to near-term claims cannot be measured from the supplied data. Claims outflows rising roughly 45% over the period increase the importance of this coverage measure, but drawing conclusions about liquidity sufficiency would be speculative. Investors should review the detailed investment and reinsurance schedules to evaluate claims-paying liquidity directly.

Reserve Estimation Risk Could Reverse Earnings

Based on Humana's reported figures, net losses of $693M in 2024Q4 and $796M in 2025Q4 coincided with combined ratios above 100%, suggesting year-end reserve or cost pressure that may recur.

The recurrence of fourth-quarter losses alongside combined ratios exceeding 103% raises the possibility that reserve adequacy, rather than one-off events, is driving balance sheet strain at year end. Because the supplied data does not isolate prior-period development or risk-adjustment clawbacks, the magnitude of potential reserve deficiencies cannot be quantified. This warrants further investigation, as an adverse reserve revision could erode equity more quickly than the current leverage profile would indicate.

HUM — Frequently Asked Questions

Quick answers to the most common questions about buying HUM stock.

What are the total assets of Humana Inc. (HUM)?

As of 2025, Humana Inc. (HUM) had total assets of $48.75B including $7.47B in current assets.

How much debt does Humana Inc. (HUM) have?

Humana Inc. (HUM) carries total debt of $12.94B, offset by $4.20B in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Humana Inc.?

Humana Inc. (HUM) has total shareholders' equity (book value) of $17.66B ($146.80 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Humana Inc.'s current ratio and liquidity?

Humana Inc. (HUM) reported a current ratio of 0.72x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.